Kynurenic acid activation of GPR35 improved cardiac function and reduced infarct scarring post-MI by suppressing pro-inflammatory macrophage responses via cGAS-STING pathway inhibition.
Does Kynurenic acid (KynA) improve cardiac function and reduce ventricular remodeling in a murine myocardial infarction model?
Kynurenic acid demonstrates cardioprotective effects post-myocardial infarction in mice by suppressing macrophage-mediated inflammation via the GPR35 and cGAS-STING pathways.
Absolute Event Rate: 0% vs 0%
Kynurenic acid (KynA), a tryptophan metabolite that regulates immune homeostasis via G protein-coupled receptor 35 (GPR35), has an undefined role in post-myocardial infarction (MI) immune responses. To clarify this role, we established a murine MI model and administered KynA intraperitoneally to evaluate cardiac function and ventricular remodeling. Macrophage infiltration was assessed, and macrophages were depleted via clodronate liposomes to confirm their contribution to KynA-mediated cardioprotection. In bone marrow-derived macrophages (BMDMs), GPR35-targeted siRNA verified the receptor-dependent action of KynA. KynA improved cardiac function, reduced infarct scarring and fibrosis, and suppressed pro-inflammatory macrophage infiltration in MI mice, with these cardioprotective effects abrogated by macrophage depletion. Mechanistically, KynA inhibited voltage-dependent anion channel 1 oligomerization, prevented mitochondrial DNA leakage, and downregulated the cGAS/STING/TBK1/IκBα/P65 pathway in macrophages, while exogenous mitochondrial DNA counteracted this inhibition. Collectively, the KynA/GPR35 axis exerts cardioprotective effects against MI by attenuating macrophage pro-inflammatory responses, highlighting its potential as a novel therapeutic target.
Mao et al. (Fri,) reported a other. Kynurenic acid activation of GPR35 improved cardiac function and reduced infarct scarring post-MI by suppressing pro-inflammatory macrophage responses via cGAS-STING pathway inhibition.